DDX53 and neoplasm: To test this, we used our “traditional” CT26-luc intravenous-injection model in which the mice received three LPP-CT26 treatments after CT26-luc tumor cell injections (Fig. 6A, left; Post), but in another cohort of mice, we also gave two additional doses of LPP-CT26 before CT26-luc cell injection, i.e., in a prophylactic (Pro) setting (Fig. 6A, right).